Back to top
more

Edwards Lifesciences (EW)

(Delayed Data from NYSE)

$68.92 USD

68.92
4,647,967

+0.80 (1.17%)

Updated Aug 16, 2024 04:00 PM ET

After-Market: $68.94 +0.02 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Insulet (PODD) Q1 Earnings Beat Estimates, Sales View Up

by Zacks Equity Research

Omnipod 5 continues to be a driving force of Insulet's (PODD) strong U.S. growth, representing almost 95% of U.S. new customer starts in the first quarter.

Bruker (BRKR) Tops Q1 Earnings Estimates, Raises '23 Outlook

by Zacks Equity Research

Bruker (BRKR) delivers a year-over-year revenue increase across all its segments in the first quarter, led by the strong demand for differentiated, high-performance scientific instruments and life-science solutions.

Bio-Rad (BIO) Q1 Earnings Beat Estimates, Operating Margin Down

by Zacks Equity Research

Bio-Rad's (BIO) first-quarter results reflect core strength across the Life Science and Clinical Diagnostics segments amid ongoing supply-chain constraints.

Amedisys (AMED) Q1 Earnings Beat Estimates, Margins Dip

by Zacks Equity Research

Amedisys (AMED) sees a year-over-year decline in the Hospice segment's revenues.

Tandem Diabetes (TNDM) Q1 Earnings Miss, Gross Margin Dips

by Zacks Equity Research

According to Tandem Diabetes (TNDM), Q1 revenues are in line with the high end of its expectations.

OPKO Health (OPK) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall first-quarter results reflect soft performances.

QuidelOrtho (QDEL) Q1 Earnings Top Estimates, FY23 View Revised

by Zacks Equity Research

Despite solid performances by the Labs segment and China region, QuidelOrtho (QDEL) reports soft overall top-line results in first-quarter 2023.

Phibro (PAHC) Q3 Earnings Miss Estimates, Gross Margin Up

by Zacks Equity Research

Higher domestic demand and higher average selling prices for dairy products and growth in the companion animal product drive Phibro's (PAHC) Q3 revenues.

Envista (NVST) Q1 Earnings Miss Estimates, Margins Down

by Zacks Equity Research

Weakness in China and Russia and lower demand for large capital equipment hurts Envista's (NVST) Q1 revenues.

BD (BDX) Q2 Earnings Surpass Estimates, FY23 View Revised

by Zacks Equity Research

BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal second quarter.

Cardinal Health (CAH) Beats on Q3 Earnings, Ups '23 EPS View

by Zacks Equity Research

Cardinal Health's (CAH) fiscal third-quarter results benefit from the Pharmaceutical segment's solid performance.

Qiagen (QGEN) Q1 Earnings Top Estimates, Operating Margin Down

by Zacks Equity Research

Amid an uncertain macroeconomic environment, Qiagen's (QGEN) first-quarter results reflect an impressive organic top line, led by strength in non-COVID-19 product groups.

Myriad Genetics (MYGN) Lags Q1 Earnings, Updates '23 View

by Zacks Equity Research

Myriad Genetics (MYGN) delivers a year-over-year increase in first-quarter revenues, reflecting a positive volume improvement across the portfolio.

Inari Medical (NARI) Q1 Earnings Top, Revenues Rise Y/Y

by Zacks Equity Research

Inari Medical's (NARI) first-quarter results benefit from significant progress made across all its growth drivers.

Glaukos' (GKOS) Q1 Earnings Beat Estimates, Sales Rise Y/Y

by Zacks Equity Research

Glaukos' (GKOS) Q1 revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to wider operating loss.

CVS Health (CVS) Q1 Earnings Surpass Estimates, EPS View Cut

by Zacks Equity Research

CVS Health's (CVS) robust sales growth across all three operating segments drives top-line results.

PacBio (PACB) Tops on Q1 Earnings, Raises FY23 Revenue View

by Zacks Equity Research

PacBio (PACB) witnesses strong revenue growth in the first quarter. This is partly aided by customers' product transition to the Revio system.

DENTSPLY SIRONA (XRAY) Q1 Earnings & Revenues Beat Estimates

by Zacks Equity Research

DENTSPLY SIRONA's (XRAY) Q1 earnings and revenues decline year over year, driven by the unfavorable foreign currency movement and soft demand across all geographical segments.

Penumbra (PEN) Q1 Earnings Top Estimates, Sales Remain Robust

by Zacks Equity Research

Penumbra's (PEN) sales during the first quarter reflect continued demand for its products. The 2023 outlook is encouraging as earnings improve despite macro challenges.

Inspire Medical (INSP) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the first quarter.

Omnicell (OMCL) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Despite a year-over-year decrease, Omnicell's (OMCL) first-quarter revenues and earnings exceed the top end of the previously announced outlook amid an uncertain macroeconomic environment.

AmerisourceBergen (ABC) Beats on Q2 Earnings, Ups '23 EPS View

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal second-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.

Zimmer Biomet (ZBH) Q1 Earnings Beat Estimates, View Raised

by Zacks Equity Research

Each of Zimmer Biomet's (ZBH) geographic segments and product divisions records strong year-over-year sales growth at CER.

Hologic's (HOLX) Q2 Earnings Beat Estimates, 2023 View Up

by Zacks Equity Research

The year-over-year growth in Breast Health and GYN Surgical Businesses contributed to Hologic's (HOLX) Q2 revenues.

IDEXX (IDXX) Q1 Earnings Beat Estimates, Margins Increase

by Zacks Equity Research

Continued solid demand for veterinary services and record global premium instrument placements drive IDEXX's (IDXX) Q1 revenues.